文献速递系统性红斑狼疮

抗疟药对狼疮性肾炎临床结局的影响

Effect of antimalarials on clinical outcomes in lupus nephritis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该回顾性研究纳入424例经活检证实的狼疮性肾炎患者,随访超过3年,评估抗疟药对治疗反应、肾脏 flares 发生率及肾病进展的影响。持续使用抗疟药3、5、7年时毒性视网膜病变发生率分别为1.7%、5.7%和8.8%,推荐每年进行眼科检查。

核心结论

  • 抗疟药使用与狼疮性肾炎患者治疗反应增加、肾脏 flares 发生率降低和进展至肾衰竭减少相关。
  • 该人群发生毒性黄斑病变的风险高,推荐每年进行眼科检查。

研究设计与样本

  • 回顾性研究纳入424例经活检证实的狼疮性肾炎患者,随访超过3年,收集中位年龄29岁(IQR 23-37)、96%女性、中位eGFR 81 ml/min/1.73 m2(IQR 48-118)和蛋白尿3.4 g/g(IQR 1.9-5.5)等资料。
  • 抗疟药使用按用户 vs 非用户、根据狼疮性肾炎 flare 的现患使用 vs 新发使用以及抗疟药类型进行分析,所有结局采用时间-事件分析,调整风险比通过Cox回归获得。

主要发现

  • 抗疟药对这些结局的影响被基线eGFR、组织学分类和/或同时使用的初始免疫抑制剂所修饰。
  • 在现患或新发使用 regarding 狼疮性肾炎 flare 的患者以及使用羟氯喹的患者中观察到这些保护效应。

关键数值与推荐

  • 毒性视网膜病变发生率:持续使用抗疟药3年1.7%、5年5.7%、7年8.8%。

临床怎么用

  • 作者推荐狼疮性肾炎患者每年进行眼科检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of antimalarial drugs in response to therapy, incidence of LN flares, and progression of kidney disease in a large LN cohort. METHODS: We retrospectively studied 424 biopsy-proven LN patients followed for >3 years. We obtained demographic, clinical, laboratory, histopathological and treatment variables. Antimalarial use was approached as (i) users vs no users, (ii) according to prevalent vs incident use regarding the LN flare and (iii) according to the type of antimalarial. All outcomes were evaluated by time-to-event analyses. Adjusted hazard ratios were obtained by Cox regression. RESULTS: The cohort included 424 patients, median age of 29 years (IQR 23-37), 96% female, with a median eGFR of 81 ml/min/1.73 m2 (IQR 48-118) and proteinuria of 3.4 g/g (IQR 1.9-5.5). Antimalarial use was associated with higher complete response (aHR 1.57, 1.08-2.27), lower incidence of kidney flares (aHR 0.63, 0.43-0.92) and lower progression to kidney failure (aHR 0.37, 0.23-0.53). The effect of antimalarials on these outcomes was modified by the presentation eGFR, histological class and/or concomitant initial immunosuppressor. These protective effects were observed in patients with prevalent or incident use regarding the LN flare and patients using hydroxychloroquine. The incidence of toxic retinopathy was 1.7%, 5.7% and 8.8% by 3, 5 and 7 years of continued antimalarial use, respectively. CONCLUSION: The use of antimalarial drugs is associated with increased response to therapy, lower incidence of kidney flares, and lower progression to kidney failure in LN patients. Conversely, this population is at high risk of toxic maculopathy, and yearly ophthalmologic examination is recommended.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Peña-Vizcarra ÓR, Zavala-Miranda MF, Juárez-Cuevas B, et al. Effect of antimalarials on clinical outcomes in lupus nephritis. Rheumatology (Oxford). 2024. PMID: 37930870. doi:10.1093/rheumatology/kead576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。